SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (931)6/28/1998 11:21:00 AM
From: Ariella  Respond to of 1491
 
Just for the record--the Israeli Consulate passes along this info:
<< The international French concern Rhone Poulence is expanding its activities in Israel in the field of pharmaceuticals, and will invest
millions of shekels in development and clinical research, GLOBES reported. The company's Israeli activities amounted to $35 million in 1997. It's involvement in the drug field focuses on the development of ethic drugs, and its main expertise lies in oncologic drugs and drugs for blood coagulation, allergies and asthma.>>

No precise connection to PARS, but another indication of how many big pharmaceuticals are coming to Israel for its expertise in R&D.



To: NeuroInvestment who wrote (931)6/29/1998 1:20:00 PM
From: Rick Strange  Read Replies (1) | Respond to of 1491
 
I can understand that PARS would like to evaluate its options: lower sales with higher gross margin or higher sales with a reduced margin but my concern about cutting the time line thin between now and the peak allergy season remain. Am I overestimating the time it would take a new marketing partner to ramp up sales within Allergy and General Practice markets?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News